Skip to main content

Advertisement

SpringerLink
Log in

Profile of atypical-antipsychotics use in patients affected by dementia in the University Hospital of Ferrara

  • Special Article
  • Published:
European Journal of Clinical Pharmacology Aims and scope Submit manuscript

Abstract

Background

The use of off-label atypical antipsychotic drugs (AA) has been noted for the treatment of behavior disorders in older patients affected by Alzheimer’s or by other forms of dementia, even though effectiveness data are limited and use seems to be associated with severe cerebrovascular risks. The data concerning such risks caused the Italian Ministry of Health to release a statement discouraging doctors from prescribing olanzapine and risperidone outside of the registered indications, in May 2004. This study aimed to analyze the prescriptive profile of AAs in patients with dementia, in terms of the choice of active substance and of the clinical characteristics of the patients.

Methods

Patients with a diagnosis of dementia and in treatment with AA (risperidone, olanzapine, and quetiapine) were selected from three main Alzheimer Evaluation Centers (Geriatrics, Neurology, Internal Medicine) of the University Hospital in Ferrara, in the period 05/2003–04/2006. For each subject, the following information was collected: the frequency of prescriptions, the drug received, and the amount of AAs in the considered period. In the third year of observation, the intensity of treatment was evaluated (intense treatment: >300 tablets of any AA; weak treatment: <300 tablets of any AA or up to three packages of risperidone drops). Such data were analyzed in terms of the type of dementia, the behavioral disturbance, and the possible presence of psychomotor agitation. In addition, the adverse reactions that occurred during the treatment were gathered. Lastly, the use of acetylcholinesterase inhibitors among the selected subjects was described.

Results

Among the 392 subjects (63% female), Alzheimer’s (49%) was the most frequent form of dementia, hallucinations were present in 50% of the cases and aggression in 53%.The statement by the Ministry of Health resulted in a foreseeable increase in the consumption of quetiapine and a parallel decrease in risperidone and olanzapine; subsequently, the distribution among the drugs stabilized to similar percentages. The doses used for the control of behavioral disturbances during dementia were on average much lower than those for treating more severe psychoses. Among the patients followed in the third year of observation (n = 159), the number of subjects in intense treatment was greater than those in weak treatment (60 vs 40%). Olanzapine was the AA most frequently used in intense dosages. Among the patients in weak treatment, about 50% used risperidone, available as oral droplets. In the patients at the Geriatric Center (n = 174), in the initial period of analysis 10 adverse events were observed and out of these 10 subjects, all of whom were under intense treatment , 8 out of 10 took quetiapine. The most frequently observed adverse events were tremors, a typical extrapyramidal symptom.

Conclusions

As physicians await next studies helping to identify specific classes of drugs for specific symptoms or subpopulations, they should turn to pharmacological treatment only after a careful risk-benefit evaluation. They should consider both the important role of the relationship between patient and carers and the adverse effects of antipsychotics, which are particularly dangerous in the elderly.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7
Fig. 8

Similar content being viewed by others

References

  1. Ott A, Breteler M, van Harskamp F (1995) Prevalence of Alzheimer’s disease and vascular dementia: association with education: the Rotterdam study. Br Med J 310:970–973

    CAS  Google Scholar 

  2. Bird TD, Miller BL. Alzheimer’s disease and other dementias. In: Kasper DL, Braunwald E, Fauci AS, et al (eds) Harrison's Internal Medicine. McGraw Hill, New York

  3. Morgan K, Lilley JM, Arie T (1993) Incidence of dementia in a representative British sample. Br J Psychiatry 163:467–470

    Article  CAS  PubMed  Google Scholar 

  4. AIFA Ministero della Salute (2006) Alzheimer e inibitori delle colinesterasi: c’è qualcosa di nuovo? Boll d’Inf Farm 13(1):19–25

    Google Scholar 

  5. Wolfson C, Wolfson DB, Asgharian M et al (2001) A reevaluation of the duration of survival after the onset of dementia. N Engl J Med 344:1111–1116

    Article  CAS  PubMed  Google Scholar 

  6. NHS National Institute for Health and Clinical Excellence (2007) NICE technology appraisal guidance 111. Donepezil, galantamine, rivastigmine (review) and memantine for the treatment of Alzheimer’s disease. NHS, London

  7. Wolfson C, Oremus M, Shukla V et al (2002) Donepezil and rivastigmine in the treatment of Alzheimer’s disease: a best evidence synthesis of the published data on their efficacy and cost-effectiveness. Clin Ther 24:862–886

    Article  CAS  PubMed  Google Scholar 

  8. Beck C, Frank L, Chumbler NR (1998) Correlates of disruptive behavior in severely cognitively impaired nursing home residents. Gerontologist 38:189–198

    CAS  PubMed  Google Scholar 

  9. Rovner BW (1992) Behavioral and psychiatric disability in Alzheimer’s disease. J Geriatr Psychiatry 25:247–255

    Google Scholar 

  10. Merriam AE, Aronson MK, Gasten P (1988) The psychiatric symptoms of Alzheimer’s disease. J Am Geriatr Soc 36:7–12

    CAS  PubMed  Google Scholar 

  11. Forbes DA, Peacock S, Morgan D (2005) Non-pharmacological management of agitated behaviors associated with dementia. Geriatrics Aging 8:26–30

    Google Scholar 

  12. Yeager BF, Farnett LE, Ruzicka SA (1995) Management of the behavior manifestations of dementia. Arch Intern Med 155:250–260

    Article  CAS  PubMed  Google Scholar 

  13. Sink KM, Holden KF, Yaffe K (2005) Pharmacological treatment of neuropsychiatric symptoms of dementia: a review of the evidence. JAMA 293:596–608

    Article  CAS  PubMed  Google Scholar 

  14. Lee PE, Gill SS, Freedman M, Bronskill SE, Hillmer MP, Rochon PA (2004) Atypical antipsychotic drugs in the treatment of behavior and psychological symptoms of dementia: systematic review. BMJ 329:75–79

    Article  PubMed  Google Scholar 

  15. Trifirò G, Spina E, Brignoli O et al (2005) Antipsychotic prescribing pattern among Italian general practitioners: a population based study during the years 1999–2002. Eur J Clin Pharmacol 61:47–53

    Article  PubMed  Google Scholar 

  16. Wooltorton E (2004) Olanzapine: increased incidence of cerebrovascular events in dementia trials. CMAJ 170:1395

    PubMed  Google Scholar 

  17. Wooltorton E (2002) Risperidone: increased rates of cerebrovascular events in dementia trials. CMAJ 167:1269

    PubMed  Google Scholar 

  18. AIFA Ministero della Salute (2004) Importanti informazioni di sicurezza su risperidone e rischio di eventi cerebrovascolari nel trattamento delle psicosi e dei disturbi comportamentali in pazienti anziani affetti da demenza. Boll d’Inf Farm 1:14

  19. AIFA Ministero della Salute (2004) Importante informazione di sicurezza su olanzapina e rischio di mortalità e ictus nel trattamento delle psicosi e dei disturbi comportamentali in pazienti anziani affetti da demenza. Boll Inf Farm 1:15

    Google Scholar 

  20. Committee on Safety of Medicines (2004) Atypical antipsychotic drugs and stroke. http://www.mhra.gov.uk/Safetyinformation/Safetywarningsalertsandrecalls/Safetywarningsandmessagesformedicines/CON1004298

  21. Ministero della Salute (2004) Chiarimenti riguardanti la prescrivibilità dei farmaci antipsicotici atipici da parte delle UVA. Farmacovigilanza News 7–8:4

    Google Scholar 

  22. FDA (2005) Public health advisory: deaths with antipsychotics in elderly patients with behavioral disturbances. http://www.fda.gov/Drugs/DrugSafety/PublicHealthAdvisories/UCM053171

  23. Wang PS, Schneeweiss S, Avorn J et al (2005) Risk of death in elderly users of conventional vs. atypical antipsychotic medications. N Engl J Med 353:2335–2341

    Article  CAS  PubMed  Google Scholar 

  24. Trifirò G, Verhamme KM, Ziere G, Caputi AP, Ch Stricker BH, Sturkenboom MC (2006) All-cause mortality associated with atypical and typical antipsychotics in demented outpatients. Pharmacoepidemiol Drug Saf 16:538–544

    Google Scholar 

  25. Schneider LS, Tariot PN, Dagerman KS et al (2006) Effectiveness of atypical antipsychotic drugs in patients with Alzheimer’s disease. N Engl J Med 12:1525–1538

    Article  Google Scholar 

  26. Ballard C, Waite J, Birks J (2006) Atypical antipsychotics for aggression and psychosis in Alzheimer’s disease. Cochrane Database Syst Rev 1:CD003476

  27. Schneider LS, Dagerman KS, Insel P (2005) Risk of death with atypical antipsychotic drug treatment. J Am Med Assoc 294(15):1934–1943

    Article  CAS  Google Scholar 

  28. Rosholm JU, Gram LF, Isacsson G, Hallas J, Bergman U (1997) Changes in the pattern of antidepressant use upon the introduction of the new antidepressants: a prescription database study. Eur J Clin Pharmacol 52:205–209

    Article  CAS  PubMed  Google Scholar 

  29. Daiello LA (2007) Atypical antipsychotics for the treatment of dementia-related behaviors: an update. Med Health R I 90:191–194

    PubMed  Google Scholar 

  30. Fossey J, Ballard C, Juszczak E et al (2006) Effects of enhanced psychosocial care on antipsychotic use in nursing home residents with severe dementia: cluster randomized trial. BMJ 332:756–761

    Article  PubMed  Google Scholar 

  31. Schneider L, Dagerman K, Insel P (2006) Efficacy and adverse effects of atypical antipsychotics for dementia: meta-analysis of randomized, placebo-controlled trials. Am J Geriatr Psychiatry 14(3):191–210

    PubMed  Google Scholar 

  32. Mulsant BH (2005) Review: pharmacotherapy provides minimal improvements in the neuropsychiatric symptoms of dementia. Evid Based Mental Health 8(3):83

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. S. Orsola University Hospital, Bologna, Italy

    Giacomo Chiabrando

  2. Department of Pharmacy, University Hospital of Ferrara, Ferrara, Italy

    Stefano Bianchi & Paola Scanavacca

  3. Department of Pharmacology, University of Bologna, Bologna, Italy

    Elisabetta Poluzzi & Nicola Montanaro

Authors
  1. Giacomo Chiabrando
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Stefano Bianchi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Elisabetta Poluzzi
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Nicola Montanaro
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Paola Scanavacca
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Stefano Bianchi.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Chiabrando, G., Bianchi, S., Poluzzi, E. et al. Profile of atypical-antipsychotics use in patients affected by dementia in the University Hospital of Ferrara. Eur J Clin Pharmacol 66, 661–669 (2010). https://doi.org/10.1007/s00228-010-0828-z

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00228-010-0828-z

Keywords

Search

Navigation